Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

V - thanks for the answer. I'm a

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
MNBioMike Member Profile
 
Followed By 8
Posts 348
Boards Moderated 0
Alias Born 09/26/18
160x600 placeholder
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Manage... GlobeNewswire Inc. - 9/3/2019 6:00:00 AM
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 8/28/2019 6:00:00 AM
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Choles... GlobeNewswire Inc. - 8/27/2019 6:00:00 AM
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference GlobeNewswire Inc. - 8/21/2019 6:00:00 AM
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm PR Newswire (US) - 8/9/2019 8:53:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 7:22:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 7/31/2019 6:34:48 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2019 6:30:41 AM
Amarin Reports Second Quarter 2019 Financial Results and Operational Update GlobeNewswire Inc. - 7/31/2019 5:00:00 AM
MNBioMike   Wednesday, 09/11/19 06:00:47 PM
Re: VuBru post# 213834
Post # of 227785 
V - thanks for the answer. I'm a CPA, but can at least understand that. ;)

I'm more curious how other drugs that were tested on top of statins received a "for statin intolerant" add-on to the label. Maybe they had a cohort to test this and we did not? Admittedly, I have not been able to dig in to this yet.

Thanks for the reply.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist